ALB and nephrolithiasis: Moreover, no related adverse (serious or non-serious) events, including nephrolithiasis (kidney stones), were observed in participants with serum calcidiol levels ≥ 100 nmol/L or with albumin-adjusted calcium levels > 2.55 mmol/L, at any of the time points.